MedTrace Logo

Effects of Imatinib Mesylate in Polycythemia Vera

NCT00430066 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2014-10-08

No results posted yet for this study

Summary

The purpose of this study is to determine the activity of Glivec 400 mg po daily, as single agent, in inducing a haematological response in Polycythemia Vera.

The patients will be asked to have additional bone marrow and blood samples collected: these samples will be used to evaluate how the disease is responding to the drug.

Conditions

Interventions

DRUG

Imatinib Mesylate

400 mg/die for 6 months

Sponsors & Collaborators

  • Niguarda Hospital

    lead OTHER

Principal Investigators

  • Enrica Morra, MD · Divisione di Ematologia - Ospedale Niguarda Ca' Granda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-11-30
Completion
2012-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430066 on ClinicalTrials.gov